AR066550A1 - Sales monoclorhidrato de un inhibidor de histona deacetilasa - Google Patents
Sales monoclorhidrato de un inhibidor de histona deacetilasaInfo
- Publication number
- AR066550A1 AR066550A1 ARP080102021A ARP080102021A AR066550A1 AR 066550 A1 AR066550 A1 AR 066550A1 AR P080102021 A ARP080102021 A AR P080102021A AR P080102021 A ARP080102021 A AR P080102021A AR 066550 A1 AR066550 A1 AR 066550A1
- Authority
- AR
- Argentina
- Prior art keywords
- forms
- monoclorhydrate
- sales
- inhibitor
- crystalline form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se refiere, además, a procesos para la produccion de dichas formas, a intermediarios utilizados en dichos procesos, a composiciones farmacéuticas que comprenden dichas formas, y a la utilizacion de dichas formas en un tratamiento médico, porejemplo, como medicamento para inhibir afecciones proliferativas, tales como, por ejemplo, cáncer y leucemia. Reivindicacion 1: Una sal monoclorhidrato de la formula (1) Reivindicacion 2: La sal monoclorhidrato de acuerdo con la reivindicacion 1,en la cual dicha sal se encuentra en forma cristalina en la Forma I, la Forma II o en-forma de hidrato. Reivindicacion 3: La sal monoclorhidrato de acuerdo con la reivindicacion 1 o 2 en la Forma I cristalina, en la cual dicha forma cristalinatiene un patron de difraccion de rayos X de polvo que comprende picos a 15,1°+- 0,2, 17,2°+- 0,2°, 23,4°+- 0,2°, 24,4°+- 0,2° y 27,7°+- 0,2°. Reivindicacion 20: Un compuesto de la formula (2), (3), (4) o (5).Un N-oxido, sal de adicion o formaestereoquímicamente isomérica de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07108176 | 2007-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066550A1 true AR066550A1 (es) | 2009-08-26 |
Family
ID=38659779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102021A AR066550A1 (es) | 2007-05-14 | 2008-05-13 | Sales monoclorhidrato de un inhibidor de histona deacetilasa |
| ARP200100716A AR118361A2 (es) | 2007-05-14 | 2020-03-13 | Sales monoclorhidrato de un inhibidor de histona deacetilasa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100716A AR118361A2 (es) | 2007-05-14 | 2020-03-13 | Sales monoclorhidrato de un inhibidor de histona deacetilasa |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20100130523A1 (es) |
| EP (1) | EP2155677B1 (es) |
| JP (1) | JP2010526851A (es) |
| KR (1) | KR101540679B1 (es) |
| CN (1) | CN101679256B (es) |
| AP (1) | AP2717A (es) |
| AR (2) | AR066550A1 (es) |
| AU (1) | AU2008250047B2 (es) |
| BR (1) | BRPI0811859B8 (es) |
| CA (1) | CA2683195C (es) |
| CL (1) | CL2008001390A1 (es) |
| CO (1) | CO6140031A2 (es) |
| CR (1) | CR11163A (es) |
| CY (1) | CY1115837T1 (es) |
| DK (1) | DK2155677T3 (es) |
| EA (1) | EA018326B1 (es) |
| EC (1) | ECSP099729A (es) |
| ES (1) | ES2525456T3 (es) |
| HK (1) | HK1140479A1 (es) |
| HR (1) | HRP20141180T1 (es) |
| IL (1) | IL202042A0 (es) |
| JO (1) | JO2959B1 (es) |
| MX (1) | MX2009012332A (es) |
| NZ (1) | NZ599674A (es) |
| PA (1) | PA8780301A1 (es) |
| PL (1) | PL2155677T3 (es) |
| PT (1) | PT2155677E (es) |
| RS (1) | RS53672B1 (es) |
| SG (1) | SG182986A1 (es) |
| SI (1) | SI2155677T1 (es) |
| TW (1) | TWI414294B (es) |
| UA (1) | UA100510C2 (es) |
| WO (1) | WO2008138918A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009015917A2 (en) | 2007-05-14 | 2009-02-05 | F. Hoffmann-La Roche Ag | Dihydroquinone and dihydronaphthridine inhibitors of jnk |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5924990B2 (ja) * | 1979-11-21 | 1984-06-13 | 協和醗酵工業株式会社 | 新規なピペリジン誘導体 |
| TR199800825T2 (xx) | 1995-12-08 | 1998-08-21 | Janssen Pharmaceutica N.V. | Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri. |
| PL1771421T3 (pl) * | 2004-07-26 | 2009-08-31 | Serono Lab | Pochodne N-hydroksyamidowe i ich zastosowanie |
| JP4948403B2 (ja) * | 2004-07-28 | 2012-06-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストン・デアセチラーゼの新インヒビターとしての置換インドリルアルキルアミノ誘導体 |
-
2008
- 2008-05-06 JO JO2008202A patent/JO2959B1/en active
- 2008-05-12 CL CL2008001390A patent/CL2008001390A1/es unknown
- 2008-05-12 PA PA20088780301A patent/PA8780301A1/es unknown
- 2008-05-13 DK DK08750252.2T patent/DK2155677T3/en active
- 2008-05-13 AP AP2009005039A patent/AP2717A/xx active
- 2008-05-13 US US12/598,743 patent/US20100130523A1/en not_active Abandoned
- 2008-05-13 SG SG2012048781A patent/SG182986A1/en unknown
- 2008-05-13 UA UAA200910196A patent/UA100510C2/ru unknown
- 2008-05-13 PT PT87502522T patent/PT2155677E/pt unknown
- 2008-05-13 BR BRPI0811859A patent/BRPI0811859B8/pt active IP Right Grant
- 2008-05-13 AR ARP080102021A patent/AR066550A1/es active IP Right Grant
- 2008-05-13 PL PL08750252T patent/PL2155677T3/pl unknown
- 2008-05-13 RS RS20140662A patent/RS53672B1/en unknown
- 2008-05-13 AU AU2008250047A patent/AU2008250047B2/en active Active
- 2008-05-13 NZ NZ599674A patent/NZ599674A/xx unknown
- 2008-05-13 ES ES08750252.2T patent/ES2525456T3/es active Active
- 2008-05-13 JP JP2010507895A patent/JP2010526851A/ja active Pending
- 2008-05-13 CA CA2683195A patent/CA2683195C/en active Active
- 2008-05-13 TW TW097117494A patent/TWI414294B/zh active
- 2008-05-13 KR KR1020097021648A patent/KR101540679B1/ko active IP Right Grant
- 2008-05-13 EA EA200971031A patent/EA018326B1/ru unknown
- 2008-05-13 CN CN2008800163514A patent/CN101679256B/zh active Active
- 2008-05-13 EP EP08750252.2A patent/EP2155677B1/en active Active
- 2008-05-13 MX MX2009012332A patent/MX2009012332A/es active IP Right Grant
- 2008-05-13 SI SI200831339T patent/SI2155677T1/sl unknown
- 2008-05-13 WO PCT/EP2008/055804 patent/WO2008138918A1/en active Application Filing
-
2009
- 2009-09-30 CO CO09107340A patent/CO6140031A2/es unknown
- 2009-11-11 EC EC2009009729A patent/ECSP099729A/es unknown
- 2009-11-11 IL IL202042A patent/IL202042A0/en active IP Right Grant
- 2009-12-14 CR CR11163A patent/CR11163A/es not_active Application Discontinuation
-
2010
- 2010-07-15 HK HK10106880.8A patent/HK1140479A1/xx unknown
-
2012
- 2012-05-30 US US13/483,678 patent/US8759519B2/en active Active
-
2014
- 2014-12-05 HR HRP20141180AT patent/HRP20141180T1/hr unknown
- 2014-12-17 CY CY20141101062T patent/CY1115837T1/el unknown
-
2020
- 2020-03-13 AR ARP200100716A patent/AR118361A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261964A (en) | Transformed gasoline compounds | |
| CY1120031T1 (el) | Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| AR090151A1 (es) | Compuestos inhibidores de raf | |
| MY196749A (en) | Eif4a-inhibiting compounds and methods related thereto | |
| WO2017075629A3 (en) | Wee 1 kinase inhibitors and methods of making and using the same | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| TN2018000119A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| UA111382C2 (uk) | Інгібітори протеїнкінази | |
| UY32096A (es) | Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones | |
| NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
| ECSP088828A (es) | 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r | |
| AR087107A1 (es) | Compuesto inhibidor de la señalizacion de la trayectoria notch | |
| CO6700837A2 (es) | Proceso de elaboración para derivados de prrimidina | |
| PH12015501945B1 (en) | Formulations of organic compounds | |
| MX2015012386A (es) | Inhibidores de la cinasa cdk9. | |
| WO2014169882A3 (zh) | 具有抗肿瘤活性的苯并咪唑类化合物、制备方法及其应用 | |
| NI201800065A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento de cáncer | |
| MX2015012153A (es) | Inhibidores de la quinasa pirrolopirimidina cdk9. | |
| AR066550A1 (es) | Sales monoclorhidrato de un inhibidor de histona deacetilasa | |
| CL2008003090A1 (es) | Forma cristalina 1 del etanoato de n-{4-(3-amino-1h-indazol-4-il)fenil}-n'-(2-fluoro-5-metilfenil)urea*1/4; procedimiento de preparacion; composicion farmaceutica que la comprende; utiles en el tratamiento del cancer. | |
| WO2013074905A3 (en) | Compounds, compositions, pharmaceutical compositions, and methods of use | |
| AR113848A1 (es) | Formas de dosificación que contienen un inhibidor calicreína de plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |